The Richard O'Reilly Lab

Richard O'Reilly Lab Group

Our laboratory has as its goal, the elucidation and therapeutic translation of the genetics and immunology of antigen-specific T-cell interactions with virus transformed and malignant cells that affect their function when used for adoptive immunotherapy in immunocompromised cancer patients and recipients of allogeneic hematopoietic or solid organ transplants. We introduced the use of transplant donor derived T-cells for the treatment of EBV lymphomas. Subsequently, we have introduced the use of banked, immediately accessible virus-specific 3rd party T-cells selected on the basis of their HLA restriction and epitope specificity for the treatment of EBV-associated malignancies and drug refractory CMV infections, as well as TCR selected and CAR modified T-cells for hematologic malignancies. To further enhance the efficacy of these T-cell therapies, we are currently evaluating epigenetic modifiers to increase and sustain tumor susceptibility to adoptive T-cell cell therapy and the biological arming of T-cells to enhance their tumor-specific activity.

Pictured: Richard O'Reilly

Richard J. O'Reilly, MD


Research Focus

Physician-scientist Richard O’Reilly investigates the genetic disparities and cellular interactions between donor and host that affect allogeneic hematopoietic cell transplantation.


MD, University of Rochester School of Medicine
  • Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O’Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted-T-cells with cytotoxic activity against WT-1+ leukemias. Blood. 2012 Aug 23;120(8):1633-46.
  • Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013 Mar 13;5(176):176ra33.
Learn more